Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis
- 811 Downloads
Idiopathic pulmonary fibrosis (IPF) produces symptoms and activity limitations that impair health-related quality of life (HRQOL). The Patient-Reported Outcomes Measurement Information System® (PROMIS®) includes measures of self-reported health and HRQOL for a range of conditions. This study evaluated the HRQOL of individuals with IPF using PROMIS measures and examined associations between HRQOL and key symptoms or supplemental oxygen need.
Individuals who reported being told by a doctor that they have IPF completed an online battery of measures at baseline and 7–10 days later (for test–retest reliability). Measures included a brief survey of demographic and health-related questions, the PROMIS-29 profile, the Modified Medical Research Council Dyspnea Scale (MMRC), PROMIS dyspnea severity short form, A Tool to Assess Quality of life in IPF (ATAQ-IPF) and one cough item from the Functional Assessment of Chronic Illness Therapy (FACIT).
220 individuals were included in the final sample. Except for sleep disturbance, all PROMIS domain scores significantly (p < .01) differed by MMRC level. Supplemental oxygen users were more impaired than non-users in fatigue, physical function, and social role participation (p < 0.01). The test–retest reliability was acceptable to excellent (>0.7) for all scales, but was lower for sleep disturbance (0.64).
People with IPF report substantial deficits in HRQOL across a range of PROMIS domains, and deficits vary by dyspnea and cough severity. These deficits warrant monitoring in clinical practice and consideration when investigating new therapies. Further research is required to further evaluate the psychometric performance of the PROMIS-29 in IPF.
KeywordsHealth-related quality of life Idiopathic pulmonary fibrosis PROMIS
The study was funded by Biogen.
Compliance with Ethical Standards
Conflict of Interest
Shih-Yin Chen is an employee and shareholder of Biogen. David Van Brunt was an employee of Biogen when the study was conducted and is a shareholder. This manuscript relates to study of disease for which Biogen is developing treatment. However, this manuscript in no way addresses the effects, or lack thereof, of any specific compound in development. The Northwestern University investigators received payment for bona-fide services in the execution of the study, but otherwise have no conflicts of interest to declare.
The Northwestern University Institutional Review Board determined that the study qualified for Exemption under United States Department of Health and Human Services CFR 46.101(b).
- 11.Rothrock NE, Hays RD, Spritzer K et al (2010) Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the patient-reported outcomes measurement information system (PROMIS). J Clin Epidemiol 63:1195–1204CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Schalet BD, Yu L, Dodds N et al. (accepted) Clinical validity of PROMIS depression, anxiety and anger across diverse clinical samples. J Clin EpidemiolGoogle Scholar
- 22.Cella D, Jensen SE, Christodoulou C et al. (accepted) Clinical validity of the PROMIS fatigue item bank across diverse clinical samples. J Clin EpidemiolGoogle Scholar
- 23.Buysse DJ, Krystal AD, Johnston K, et al. Sleep and health-related function in a clinical sample as measured by PROMIS (patient-reported outcomes measurement information system). In: 26th Annual Meeting of the Associated Professional Sleep Societies, Sleep 2012, vol 35, pp A133–A133Google Scholar
- 25.Hinchcliff M, Beaumont JL, Thavarajah K et al (2011) Validity of two new patient-reported outcome measures in systemic sclerosis: patient-reported outcomes measurement information system 29-item health profile and functional assessment of chronic illness therapy–dyspnea short form. Arthr Care Res 63:1620–1628CrossRefGoogle Scholar